Fenoprolic® is Eevia's flagship product and contains 70% of OPCs (Oligomeric proanthocyanidins). Pycnogenol® has the same concentration of OPC (70%) and is marketed worldwide by
Eevia undertook an extensive study of the bioactivity of Fenoprolic® and is the market leader with the Eurofins BioMAP® Human Primary Cell Phenotypic profiling platform. The Eurofins platform contains over 150 biomarkers across a range of bioactivity systems. Eurofins tested Fenoprolic® and Pycnogenol® in the same way, on the same biomarkers, and on the same human primary cells, which makes the comparison of the bioactivity profile relevant both in quality and magnitude. Eurofins then compared the bioactivity profiles.
Eevia considers the near-identical results remarkable, and Eevia expects that the new information will immediately trigger new sales orders and contracts from customers and prospects.
The research article also promotes this form of bioactivity profiling as a way of showing bioequivalence between products or not, which can also be used to differentiate from imposter products, adulterated ingredients, and products with mostly sugar and flavors but little or no bioactive compounds ("Candyceuticals").
"The BioMAP comparison of our pine bark extract against the market leader is compelling and confirms that our product is nearly identical in vitro bioactivity to the market leader. Substantiating bioactivity in human primary cells can support sales traction and order updates from the marketplace, " comments
For further information, please contact:
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
To learn more, please visit www.eeviahealth.com or follow
https://news.cision.com/eevia-health/r/eevia-health-plc-publishes-a-new-research-article-comparing-fenoprolic--and-pycnogenol-,c3972293
https://mb.cision.com/Main/20679/3972293/2774870.pdf
https://mb.cision.com/Public/20679/3972293/820f26856902fbc7.pdf
https://news.cision.com/eevia-health/i/img-4355-003,c3296206
(c) 2024 Cision. All rights reserved., source